3h agoInvesting.com MarketsBEARISH 38General
Why is Travere Therapeutics stock sliding today?
Why is Travere Therapeutics stock sliding today?
Why Is TRAVERE THERAPEUTICS (TVTX) Stock Moving Today?
By the Top Tier Newswire AI Desk · August 6, 2026 at 12:25 AM ET · reviewed against 11 wire stories
TRAVERE THERAPEUTICS (TVTX) is drawing unusual attention today. Our newswire has captured 11 stories on TVTX across 7 sources in the last 36 hours, with AI sentiment reading mixed (avg 50/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Travere Therapeutics (TVTX) surged 12.03% to $62.76 in a single session, driven by strong second quarter results and analyst upgrades. The stock’s performance was fueled by a 96% year-over-year increase in FILSPARI sales and a positive reception of its FSGS launch. Analysts from multiple firms raised price targets, reflecting confidence in the company’s growth trajectory.
What Happened
Travere Therapeutics reported second quarter 2026 results on August 4, 2026, with FILSPARI sales rising 96% year-over-year and 2,012 new patient starts. The company also announced $141 million in revenue and a peak annual FILSPARI sales potential of more than $3 billion. These results were highlighted in an SEC 8-K filing and discussed during the company’s earnings call on August 4. The FSGS launch has exceeded expectations, contributing to the stock’s upward momentum. In addition, Stifel, TD Cowen, Citigroup, Evercore ISI Group, and Guggenheim all raised price targets for the stock, reinforcing investor confidence.
What The Data Shows
Travere Therapeutics closed at $62.76, a 12.03% increase for the session. The stock has traded between $15.42 and $60.10 over the past 52 weeks, indicating a strong upward trend. The company has a market capitalization of $5.1 billion and reported revenue growth of 96% TTM, despite an unprofitable status with an EPS TTM of -0.51 and a net margin of -4.0%. Recent insider transactions show three sales totaling $867,000 over the past 90 days, with no insider buying reported.
What To Watch
Travere Therapeutics is scheduled to participate in investor conferences, with the first presentation on August 11. The company’s continued performance in FILSPARI sales and FSGS launch progress will be key indicators for future stock movement. Investors should also monitor analyst coverage and any further price target adjustments.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
TVTX by the numbers
7 sessions: -6.05%Coverage: 11 stories / 7 sourcesAI sentiment: 50/100 (mixed)Mkt cap: $5.1B52w: $15.42 to $60.10
The headlines behind the move
5h agoThe FlyBULLISH 63Analyst
Buy Travere Therapeutics on weakness, says Cantor Fitzgerald
11h agoGuruFocusBEARISH 42General
TVTX SWOT Analysis: Financial Struggles Amidst Growth Potential Revealed in 10-Q Filing
12h agoSeeking AlphaBULLISH 64Product/PR
Travere targets $3B FILSPARI sales by 2033 as patent terms extend into 2037
Travere Therapeutics Q3 2026 earnings: FILSPARI sales topped $200M, patent runway extended to 2037, and Q4 headwinds loom.
12h agoSeeking AlphaNEUTRAL 50Earnings
Travere Therapeutics, Inc. (TVTX) Q3 2026 Earnings Call Transcript
Travere Therapeutics, Inc. (TVTX) Q3 2026 Earnings Call November 2, 2026 4:30 PM ESTCompany ParticipantsEric Dube - President, CEO & DirectorPeter...
12h agoThe Motley FoolBULLISH 64Earnings
Travere (TVTX) Q3 2026 Earnings Call Transcript
FILSPARI sales hit $200.2 million as FSGS launches alongside sustained IgAN demand.
12h agoGuruFocusNEUTRAL 50Earnings
Q3 2026 Travere Therapeutics, Inc. Earnings Call Transcript
20h agoSeeking AlphaBEARISH 42Earnings
Travere Therapeutics Non-GAAP EPS of -$0.31 misses by $0.73, revenue of $224.5M beats by $29.21M
Travere Therapeutics Q3 results: revenue beat on 36% growth, but EPS missed as R&D and SG&A rose.
20h agoThe FlyBEARISH 34Earnings
Travere Therapeutics reports Q3 EPS (31c), consensus 42c
20h agoSEC 8-KNEUTRAL 50General
Travere Therapeutics, Inc. (TVTX) files 8-K
Filed: 2026-11-02 AccNo: 0001438533-26-000074 Size: 431 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Frequently asked questions
Why is TVTX stock moving today?
TRAVERE THERAPEUTICS (TVTX) is drawing unusual attention today. Our newswire has captured 11 stories on TVTX across 7 sources in the last 36 hours, with AI sentiment reading mixed (avg 50/100). The most recent driver: "Why is Travere Therapeutics stock sliding today?" (Investing.com Markets).
Is TVTX a buy right now?
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of TVTX coverage reads 50/100 over 11 stories; treat it as a research signal and do your own diligence.
How fast does this page update?
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More moves explained today
- Why is IBTA up today (+27.66%)
- Why is STVN down today (-24.77%)
- Why is AEHR up today (+23.21%)
- Why is BVS down today (-19.58%)
- Why is GPK up today (+19.02%)
- Why is BCAX up today (+17.09%)
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on TVTX: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.